跳至主要内容

Medicilon's Immuno-oncology Models Evaluation Platform

 Immuno-oncology Model

In recent years, tumor immunotherapy has become the core of cancer treatment research. With innovation as the driving force, Medicilon has vigorously developed a tumor immunity (Immuno-oncology) drug efficacy evaluation research platform. Currently, CAR-T, TCR-T, CAR-NK, Oncolytic Virus, antibodies (monoclonal antibodies, double antibodies, polyclonal antibodies, etc.), siRNA, AAV, and other immunotherapy models and methods for evaluating the efficacy of immunotherapy, empower the research process of innovative therapies and protect health!

Syngenic Models

The homologous tumor transplantation model tests the ability of model animals to use their perfect immune system to fight cancer and the therapeutic effect of immunotherapy.The choices we offer you are:

Types of Syngenic Models
Types of Syngenic Models

Classification of immune cells in model blood by flow cytometry

PBMC Humanized Models

The humanized tumor mouse model of a partially reorganized human immune system is particularly effective for short-term or high-throughput research.

The types of models currently available for Medicilon are:

PBMC Humanized Models

Tumor growth and drug efficacy evaluation of PBMC humanized mouse lymphoma transplantation model.

PBMC humanized mouse lymphoma transplantation model

CD34+ HSC Humanized Models

Humanized mice transplanted with CD34+ human umbilical cord blood cells to reconstruct the human hematopoietic system are colonized in the mouse bone marrow and continuously and stably produce various human hematopoietic cells and immune cells and use the human immune system to evaluate multiple immunotherapy.

Medicilon’s currently available models are:

CD34+ HSC Humanized Models


Orthotopic Model

The xenogeneic orthotopic tumor transplantation model can fully consider the interaction of tumor cells and the organ microenvironment between the surrounding stroma and monitor tumor growth when evaluating drug efficacy.

Medicilon will break the barriers of experimentation and technology for you. At present, it has mature orthotopic transplantation technology, including orthotopic brain transplantation, orthotopic liver transplantation, orthotopic lung transplantation, orthotopic transplantation of tibia marrow cavity, orthotopic intravesical transplantation Transplant, etc.

Orthotopic brain transplantation

Orthotopic brain transplantation

Lung metastasis model

Lung metastasis model

Tibia bone marrow cavity orthotopic transplantation

Tibia bone marrow cavity orthotopic transplantation

Orthotopic ovarian cancer transplantation

Orthotopic ovarian cancer transplantation

PDX Models

The human tumor transplantation model PDX retains the characteristics of the patient’s tumor tissue and is more clinically relevant. It can establish an ideal tumor immunotherapy evaluation model combined with humanized mice. Medicilon has now developed:

Medicilon’s PDX model research includes molecular-level genotyping and tumor model pharmacological efficacy evaluation services, providing a highly predictive model for clinical efficacy study.

contact us
Email: marketing@medicilon.com
Tel: +86 (21) 5859-1500

标签：

评论

发表评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou
发表评论
阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d
发表评论
阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati
发表评论
阅读全文